Brokerages Set Perspective Therapeutics, Inc. (NYSE:CATX) Price Target at $19.80

Perspective Therapeutics, Inc. (NYSE:CATX) has received an average rating of “Buy” from the seven research firms that are currently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $19.80.

Several research firms have recently weighed in on CATX. Bank of America initiated coverage on shares of Perspective Therapeutics in a report on Thursday, July 25th. They set a “buy” rating and a $24.00 price objective for the company. Oppenheimer dropped their price target on Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. Royal Bank of Canada reduced their price objective on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research note on Friday, August 16th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th.

Perspective Therapeutics Trading Down 1.8 %

Shares of CATX stock opened at $13.23 on Monday. The company has a fifty day moving average of $13.81. Perspective Therapeutics has a one year low of $2.20 and a one year high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its earnings results on Monday, August 12th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.04. The firm had revenue of $0.53 million during the quarter. Research analysts expect that Perspective Therapeutics will post -0.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. ZWJ Investment Counsel Inc. acquired a new position in shares of Perspective Therapeutics during the first quarter valued at $26,000. Simplicity Wealth LLC acquired a new position in Perspective Therapeutics during the 1st quarter valued at about $40,000. Bleakley Financial Group LLC bought a new position in shares of Perspective Therapeutics in the 1st quarter valued at about $40,000. Victory Capital Management Inc. acquired a new stake in shares of Perspective Therapeutics during the 2nd quarter worth approximately $117,000. Finally, Point72 DIFC Ltd acquired a new stake in shares of Perspective Therapeutics during the 2nd quarter worth approximately $118,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.